All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

JSP191 conditioning for patients with AML or MDS: Preliminary results from a phase I clinical trial

Feb 24, 2021

During the 2021 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, positive preliminary data from a phase I trial (NCT04429191), evaluating JSP191 as a conditioning agent prior to hematopoietic stem cell transplantation (HSCT) in older patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), was presented as a late-breaking abstract by Lori Muffly, Stanford Medicine.1,2


JSP191 is a first-in-class, humanized, anti-CD117 monoclonal antibody that has demonstrated safe depletion of normal and diseased hematopoietic stem cells in preclinical studies. CD117 is a stem cell factor receptor integral to the survival of hematopoietic stem and progenitor cells. JSP191 perturbs crucial survival pathways, resulting in stem cell death, which allows for the engraftment of transplanted stem cells.1

Study design

The multi-center, open-label, phase I dose escalation study is investigating the safety, tolerability, and efficacy of JSP191 plus low-dose radiation and fludarabine as a targeted conditioning regimen prior to HSCT in patients aged 65–74 with AML or MDS who are ineligible for full myeloablative conditioning. Primary outcomes of the study were safety and tolerability of JSP191 as a conditioning regimen.1

Preliminary data

All six patients who received a single dose of JSP191 at 0.6 mg/kg as a conditioning agent experienced successful engraftment following transplantation. Five of the six patients achieved complete donor myeloid chimerism, which persisted in all three of the evaluable patients at Day 90. Of the five patients evaluable for measurable residual disease (MRD) at Day 28, three demonstrated complete MRD negativity by next-generation sequencing, and two patients exhibited considerable reductions in MRD. Across the six patients, no treatment-related serious adverse events were described.1,2


JSP191 was designed with the aim to provide a well-tolerated and effective outpatient conditioning option for newborn and older patients. These early data show that JSP191, in combination with a standard non-myeloablative regimen, demonstrates encouraging tolerability and efficacy in elderly patients with AML and MDS.

  1. Jasper Therapeutics. Jasper Therapeutics announces positive data from phase 1 clinical trial of JSP191 as targeted stem cell conditioning agent in patients with myelodysplastic syndromes or acute myeloid leukemia undergoing hematopoietic cell transplantation. Published Feb 8, 2021. Accessed Feb 23, 2021.
  2. Phase 1 study of JSP191, an anti-CD117 monoclonal antibody, with low dose irradiation and fludarabine in older adults with MRD-positive AML/MDS undergoing allogeneic HCT. Poster LBA5. 2021 TCT Meetings of ASTCT and CIBMTR ; Feb 8, 2021; Virtual.

More about...


Subscribe to get the best content related to AML delivered to your inbox